Published: 26 October 2021
Author(s): Anat Achiron, Mathilda Mandel, Sapir Dreyer-Alster, Gil Harari, Michael Gurevich
Issue: January 2022
Section: Letter to the Editor

The most effective approach to fight COVID-19 infection is prevention by targeted vaccines that prime the immune system prior to a first encounter with the virus. The BNT162b2 messenger RNA (mRNA) vaccine encoding the SARS-CoV-2 full length spike generates antibodies that prevent the entry of the virus into cells by blocking either ACE2–RBD binding interactions or spike-mediated membrane fusion [1]. The vaccine proved efficient in a large multinational trial, including 21,720 subjects vaccinated with BNT162b2.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.